Vanzacaftor
- Generic Name
- Vanzacaftor
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C32H39N7O4S
- CAS Number
- 2374124-49-7
- Unique Ingredient Identifier
- COM1POP492
- Associated Conditions
- -
- Associated Therapies
- -
An Electrocardiogram Study to Evaluate the Effect of Vanzacaftor on the QT/QTc Interval in Healthy Participants
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2023-05-19
- Last Posted Date
- 2023-07-14
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 56
- Registration Number
- NCT05867147
- Locations
- 🇺🇸
Celerion - Tempe, Tempe, Arizona, United States
A Study to Evaluate the Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic Fibrosis
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2019-04-11
- Last Posted Date
- 2023-04-20
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 87
- Registration Number
- NCT03912233
- Locations
- 🇳🇱
HagaZiekenhuis van den Haag, Den Haag, Netherlands
🇳🇱Erasmus Medical Center, Rotterdam, Netherlands
🇺🇸Tulane Medical Center, New Orleans, Louisiana, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath